CNS Portfolio Strength Supernus has a broad and growing CNS portfolio with approved treatments across ADHD, Parkinson’s-related dyskinesia, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, plus a strategy to expand into epilepsy and depression. This presents potential cross-sell opportunities with specialty distributors and value-based conversations with payers highlighting diversified CNS options.

Recent Acquisitions Strategic acquisitions of CNS portfolios from US WorldMeds (2020), Adamas (2021), and Sage Therapeutics (2025) indicate an active expansion mindset and potential for synergistic product integrations. Business development can target late-stage or complementary CNS assets for accelerated market penetration and pipeline acceleration.

Revenue Growth Signals Full-year 2025 revenue reached roughly $719 million with growth of about 9 percent year-over-year, signaling solid demand and rebound resilience despite generic competition affecting Trokendi XR and Oxtellar XR. Opportunities exist to position newer therapies or reformulations to mitigate erosion from generics.

Competitive Landscape There is ongoing antitrust and patent litigation activity related to acquisitions and distribution rights, underscoring a competitive and legal considerations environment. BD strategies should emphasize differentiated CNS mechanisms, robust patent strategies, and partnerships with manufacturers or distributors that enhance exclusivity and market access.

Operational Readiness The company leverages a modern tech stack (SAS, AWS, Salesforce, CrowdStrike, SAP Concur, among others) and has a sizable workforce focused on CNS development. This suggests capacity for rapid onboarding of new partnerships, scalable commercialization efforts, and robust data-driven sales enablement to support product launches and market access initiatives.